Validation of Random Forest Machine Learning Models to Predict Dementia-Related Neuropsychiatric Symptoms in Real-World Data.


Journal

Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863

Informations de publication

Date de publication:
2020
Historique:
pubmed: 4 8 2020
medline: 10 9 2021
entrez: 4 8 2020
Statut: ppublish

Résumé

Neuropsychiatric symptoms (NPS) are the leading cause of the social burden of dementia but their role is underestimated. The objective of the study was to validate predictive models to separately identify psychotic and depressive symptoms in patients diagnosed with dementia using clinical databases representing the whole population to inform decision-makers. First, we searched the electronic health records of 4,003 patients with dementia to identify NPS. Second, machine learning (random forest) algorithms were applied to build separate predictive models for psychotic and depressive symptom clusters in the training set (N = 3,003). Third, calibration and discrimination were assessed in the test set (N = 1,000) to assess the performance of the models. Neuropsychiatric symptoms were noted in the electronic health record of 58% of patients. The area under the receiver operating curve reached 0.80 for the psychotic cluster model and 0.74 for the depressive cluster model. The Kappa index and accuracy also showed better discrimination in the psychotic model. Calibration plots indicated that both types of model had less predictive accuracy when the probability of neuropsychiatric symptoms was <25%. The most important variables in the psychotic cluster model were use of risperidone, level of sedation, use of quetiapine and haloperidol and the number of antipsychotics prescribed. In the depressive cluster model, the most important variables were number of antidepressants prescribed, escitalopram use, level of sedation, and age. Given their relatively good performance, the predictive models can be used to estimate prevalence of NPS in population databases.

Sections du résumé

BACKGROUND
Neuropsychiatric symptoms (NPS) are the leading cause of the social burden of dementia but their role is underestimated.
OBJECTIVE
The objective of the study was to validate predictive models to separately identify psychotic and depressive symptoms in patients diagnosed with dementia using clinical databases representing the whole population to inform decision-makers.
METHODS
First, we searched the electronic health records of 4,003 patients with dementia to identify NPS. Second, machine learning (random forest) algorithms were applied to build separate predictive models for psychotic and depressive symptom clusters in the training set (N = 3,003). Third, calibration and discrimination were assessed in the test set (N = 1,000) to assess the performance of the models.
RESULTS
Neuropsychiatric symptoms were noted in the electronic health record of 58% of patients. The area under the receiver operating curve reached 0.80 for the psychotic cluster model and 0.74 for the depressive cluster model. The Kappa index and accuracy also showed better discrimination in the psychotic model. Calibration plots indicated that both types of model had less predictive accuracy when the probability of neuropsychiatric symptoms was <25%. The most important variables in the psychotic cluster model were use of risperidone, level of sedation, use of quetiapine and haloperidol and the number of antipsychotics prescribed. In the depressive cluster model, the most important variables were number of antidepressants prescribed, escitalopram use, level of sedation, and age.
CONCLUSION
Given their relatively good performance, the predictive models can be used to estimate prevalence of NPS in population databases.

Identifiants

pubmed: 32741825
pii: JAD200345
doi: 10.3233/JAD-200345
pmc: PMC7592688
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

855-864

Références

Neuroepidemiology. 2014;43(1):28-37
pubmed: 25323155
Neurologia (Engl Ed). 2021 Jul-Aug;36(6):418-425
pubmed: 34238524
Int Psychogeriatr. 2007 Jun;19(3):345-54
pubmed: 17386120
Value Health. 2019 Jul;22(7):808-815
pubmed: 31277828
Int J Geriatr Psychiatry. 2019 Mar;34(3):420-431
pubmed: 30430642
J Alzheimers Dis. 2015;48(3):721-30
pubmed: 26402090
PLoS One. 2018 Aug 6;13(8):e0201904
pubmed: 30080866
Neuroimage Clin. 2019;23:101837
pubmed: 31078938
Alzheimers Dement (N Y). 2019 Jul 09;5:272-293
pubmed: 31334330
Lancet. 2011 Mar 19;377(9770):1019-31
pubmed: 21371747
Neurology. 1994 Dec;44(12):2308-14
pubmed: 7991117
BMC Geriatr. 2016 May 18;16:106
pubmed: 27193287
Neuropsychiatr Dis Treat. 2019 Jul 17;15:2027-2034
pubmed: 31413574
J Clin Psychiatry. 2015 Oct;76(10):1346-53
pubmed: 26528641
J Alzheimers Dis. 2016 Aug 10;54(1):337-49
pubmed: 27567819
Front Neurol. 2012 May 07;3:73
pubmed: 22586419
J Alzheimers Dis. 2018;65(3):855-869
pubmed: 28731432
N Engl J Med. 2016 Sep 29;375(13):1216-9
pubmed: 27682033
Int Psychogeriatr. 2015 Jan;27(1):7-17
pubmed: 25311499
Nat Rev Neurosci. 2007 Mar;8(3):233-9
pubmed: 17299455
Clin Epidemiol. 2019 Mar 04;11:217-228
pubmed: 30881138
Alzheimers Dement (N Y). 2017 Aug 05;3(3):440-449
pubmed: 29067350
J Am Geriatr Soc. 2019 Feb;67(2):269-276
pubmed: 30315744
JAMA. 2002 Sep 25;288(12):1475-83
pubmed: 12243634
J Alzheimers Dis. 2019;67(2):495-501
pubmed: 30584137
J Affect Disord. 2016 Jan 15;190:264-271
pubmed: 26540080
Rev Esp Cardiol. 2011 Sep;64(9):788-94
pubmed: 21763052
JAMA. 2014 Feb 19;311(7):682-91
pubmed: 24549548
Ann Intern Med. 2015 Jan 6;162(1):55-63
pubmed: 25560714
Biogerontology. 2017 Apr;18(2):171-188
pubmed: 28265788
Lancet. 2012 Oct 20;380(9851):1441-3
pubmed: 23084456
BMC Med Res Methodol. 2018 Dec 29;18(1):179
pubmed: 30594138
Drug Saf. 2017 Aug;40(8):679-692
pubmed: 28439716
J Clin Psychopharmacol. 2017 Apr;37(2):138-147
pubmed: 28141623
Eur J Clin Invest. 2012 Feb;42(2):216-28
pubmed: 21726217
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571

Auteurs

Javier Mar (J)

Basque Health Service (Osakidetza), Debagoiena Integrated Healthcare Organisation, Research Unit, Arrasate-Mondragón, Guipúzcoa, Spain.
Kronikgune Institute for Health Service Research, Barakaldo, Spain.
Biodonostia Health Research Institute, Donostia-San Sebastán, Guipúzcoa, Spain.
Health Services Research on Chronic Patients Network (REDISSEC), Bilbao, Vizcaya, Spain.

Ania Gorostiza (A)

Basque Health Service (Osakidetza), Debagoiena Integrated Healthcare Organisation, Research Unit, Arrasate-Mondragón, Guipúzcoa, Spain.
Kronikgune Institute for Health Service Research, Barakaldo, Spain.

Oliver Ibarrondo (O)

Basque Health Service (Osakidetza), Debagoiena Integrated Healthcare Organisation, Research Unit, Arrasate-Mondragón, Guipúzcoa, Spain.
Kronikgune Institute for Health Service Research, Barakaldo, Spain.
Biodonostia Health Research Institute, Donostia-San Sebastán, Guipúzcoa, Spain.

Carlos Cernuda (C)

Mondragon Unibertsitatea, Faculty of Engineering, Electronics and Computing Department, Arrasate-Mondragon, Gipuzkoa, Spain.

Arantzazu Arrospide (A)

Basque Health Service (Osakidetza), Debagoiena Integrated Healthcare Organisation, Research Unit, Arrasate-Mondragón, Guipúzcoa, Spain.
Kronikgune Institute for Health Service Research, Barakaldo, Spain.
Biodonostia Health Research Institute, Donostia-San Sebastán, Guipúzcoa, Spain.
Health Services Research on Chronic Patients Network (REDISSEC), Bilbao, Vizcaya, Spain.

Álvaro Iruin (Á)

Biodonostia Health Research Institute, Donostia-San Sebastán, Guipúzcoa, Spain.
Basque Health Service (Osakidetza), Gipuzkoa Mental Health Network, Donostia-San Sebastián, Guipúzcoa, Spain.

Igor Larrañaga (I)

Basque Health Service (Osakidetza), Debagoiena Integrated Healthcare Organisation, Research Unit, Arrasate-Mondragón, Guipúzcoa, Spain.
Kronikgune Institute for Health Service Research, Barakaldo, Spain.

Mikel Tainta (M)

Kronikgune Institute for Health Service Research, Barakaldo, Spain.
Department of Neurology, Basque Health Service (Osakidetza), Goierri-Urola Garaia Integrated Healthcare Organisation, Zumarraga, Guipúzcoa, Spain.
Fundación CITA-Alzheimer Fundazioa, Donostia-San Sebastián, Guipúzcoa, Spain.

Enaitz Ezpeleta (E)

Mondragon Unibertsitatea, Faculty of Engineering, Electronics and Computing Department, Arrasate-Mondragon, Gipuzkoa, Spain.

Ane Alberdi (A)

Mondragon Unibertsitatea, Faculty of Engineering, Electronics and Computing Department, Arrasate-Mondragon, Gipuzkoa, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH